Presentation is loading. Please wait.

Presentation is loading. Please wait.

IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells. IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells.

Published byHerman Lie Modified over 5 years ago

Similar presentations

Presentation on theme: "IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells. IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells."— Presentation transcript:

1 IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells.
IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells. FaDu cells were pretreated with 100 ng/mL of human recombinant IL-6 for 2 hours before treatment with or without 5 μmol/L erlotinib (ERL) for 48 hours. Treated cells were analyzed for cytotoxicity via clonogenic analysis (A). DMSO was used as a control (CON). FaDu cells were treated with 1 μmol/L of the IL-6 receptor antagonist tocilizumab (TOC) or IgG with or without 5 μmol/L erlotinib (ERL) for 48 hours then analyzed by clonogenic assay (B). Athymic (nu/nu) mice bearing FaDu (C) and SQ20B (D) xenograft tumors were treated with 1 mg/mouse tocilizumab (TOC) and/or 12 mg/kg erlotinib (ERL) for 10 days. Tocilizumab was given intraperitoneally every other day and erlotinib was given by oral gavage every day. Control mice (CON) received IgG. Data points represent the average values for 9 mice. Error bars represent the SEM. *P < 0.05 versus DMSO or IgG control. **P < 0.05 versus ERL. Elise V.M. Fletcher et al. Mol Cancer Res 2013;11: ©2013 by American Association for Cancer Research

Download ppt "IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells. IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells."

Similar presentations

Drug concentration (μM)

Drug concentration (μM)
A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.

A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.
SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.
Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
FL cells are dependent on BCL6 in a NOTCH2-dependent manner.

FL cells are dependent on BCL6 in a NOTCH2-dependent manner.
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
H31m1-PDL1 cells form progressively growing tumors in WT mice.

H31m1-PDL1 cells form progressively growing tumors in WT mice.
Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.
The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.
Overexpression of HGF decreases MET protein levels.

Overexpression of HGF decreases MET protein levels.
Figure 5 ADP-induced inflammatory responses require P2Y12 receptors in human microgliaIncreasing concentrations of ADP (5, 50, and 200 μM) increased tumor.

Figure 5 ADP-induced inflammatory responses require P2Y12 receptors in human microgliaIncreasing concentrations of ADP (5, 50, and 200 μM) increased tumor.
Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts.

Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts.
TDP1 knockdown increases the sensitivity of rhabdomyosarcoma cell lines to CPT treatment. TDP1 knockdown increases the sensitivity of rhabdomyosarcoma.

TDP1 knockdown increases the sensitivity of rhabdomyosarcoma cell lines to CPT treatment. TDP1 knockdown increases the sensitivity of rhabdomyosarcoma.
Activity of MAC-321 (i. v. and p. o

Activity of MAC-321 (i. v. and p. o
ONC201 activates the ISR. ONC201 activates the ISR. (A) Western blotting analysis for ATF4, CHOP, ATF3, and TRB3 on lysates from HCT116 cells cultured.

ONC201 activates the ISR. ONC201 activates the ISR. (A) Western blotting analysis for ATF4, CHOP, ATF3, and TRB3 on lysates from HCT116 cells cultured.

Similar presentations

Ads by Google